Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Forepont Capital Partners is a global asset manager based in New York, founded in 2017. The firm initially began operations in 2011, financing medical research in neurology. Over the years, Forepont has evolved into a prominent player in the healthcare and life sciences sectors, establishing partnerships with physicians, researchers, and pharmaceutical groups to bolster its investment and research initiatives.
Currently, Forepont Capital Partners manages a diverse portfolio of investments, focusing on biotech, medtech, and e-health startups primarily in North America and Europe. The firm operates with a unique philanthropy-investment hybrid model, which allows it to fund basic research while simultaneously investing in startups that emerge from these scientific endeavors. This approach not only enhances the performance of its portfolio companies but also contributes to advancements in medical science.
As of now, Forepont has not publicly disclosed its total assets under management (AUM) or the specific number of funds it operates. However, its commitment to supporting healthcare innovation is evident through its extensive partnerships and active investment strategy.
Forepont Capital Partners invests in a range of sectors, including biotech, medtech, and e-health, with a strong emphasis on healthcare innovation. The firm targets startups at various stages, from pre-seed to growth equity, with check sizes ranging from $1 million to $10 million. This flexibility allows Forepont to engage with companies at critical points in their development, particularly before they reach the inflection point in their growth trajectories.
The firm primarily focuses its investments in North America and Europe, where it seeks to provide scientific, technological, financial, and operational support to enhance the performance of its portfolio companies. Forepont's investment strategy is characterized by a thorough consideration of the medical, human, financial, and ethical implications of each investment, ensuring that its contributions align with broader societal goals.
Forepont Capital Partners emphasizes the importance of partnerships with researchers and industry stakeholders, which enhances its ability to support startups effectively. This collaborative approach is integral to the firm's investment thesis, which prioritizes scientific and technological advancements in the healthcare sector.
Forepont Capital Partners has built a diverse portfolio of innovative companies across various healthcare sectors. Notable companies in its portfolio include:
This portfolio reflects Forepont's commitment to investing in groundbreaking technologies that address critical healthcare challenges.
Eric M. Attias - Founder. Eric has extensive experience in venture capital and healthcare investments, having founded Forepont Capital Partners to focus on healthcare innovation.
Dr. Ismail Kola - Partner. Dr. Kola brings a wealth of knowledge in biotechnology and has led numerous successful investments in the sector.
Frederic Batoua - Partner. Frederic has a strong background in finance and investment management, contributing to Forepont's strategic direction.
Guillaume Bouyoux - Vice President. Guillaume specializes in operational support for portfolio companies, leveraging his expertise in healthcare technology.
Bruce Greenberg - Partner. Bruce has a proven track record in venture capital, focusing on early-stage investments in healthcare.
Philippe Louisadat - Partner. Philippe's experience in the pharmaceutical industry enhances Forepont's investment strategy.
Louis Moulin - Vice President. Louis supports portfolio companies with operational and strategic guidance.
Larry Rubin - Partner. Larry has extensive experience in healthcare investments and contributes to deal sourcing and evaluation.
Doug Siekierski - Partner. Doug focuses on identifying innovative startups in the biotech and medtech sectors.
Laurent Bouyoux - Board Member. Laurent provides strategic oversight and guidance to the firm.
Geoff Kalish - Board Member. Geoff's expertise in venture capital supports Forepont's investment decisions.
David Norton - Board Member. David brings a wealth of experience in healthcare investments to the board.
Gilles Pagniez - Board Member. Gilles provides insights into the pharmaceutical industry, enhancing the firm's strategic direction.
Dr. Philippe Schaison - Board Member. Dr. Schaison's background in medical research informs Forepont's investment approach.
Per Wold-Olsen - Board Member. Per contributes to the firm's governance and strategic planning.
To pitch to Forepont Capital Partners, startups should use a warm introduction whenever possible. A detailed pitch deck should include information on the business model, market potential, and the technology's scientific basis. Founders can expect a response within a few weeks, depending on the volume of inquiries.
In December 2023, Forepont Capital Partners participated in a EUR 6 million Series A funding round for BCV, a company focused on disruptive biotech and medtech innovations. This investment highlights Forepont's active role in supporting early-stage companies within the healthcare sector.
Forepont has been recognized as an international venture capital firm that invests in groundbreaking startups, particularly in the biotech and medtech fields. The firm continues to build its portfolio, reflecting its commitment to advancing healthcare innovation.
What are Forepont Capital Partners' investment criteria?
Forepont Capital Partners focuses on investing in biotech, medtech, and e-health startups. The firm emphasizes scientific, technological, financial, and operational support to enhance the performance of these companies. Investments are typically made before the inflection point in their growth trajectories.
How can startups apply or pitch to Forepont Capital Partners?
Startups interested in pitching to Forepont should prepare a comprehensive deck that outlines their business model, market opportunity, and technological innovations. While specific application forms are not mentioned, a warm introduction through industry connections may enhance the chances of engagement.
What makes Forepont Capital Partners different from other venture capital firms?
Forepont operates a unique philanthropy-investment hybrid model, funding basic research while investing in resulting startups. This dual approach allows the firm to support scientific advancements alongside commercial ventures, distinguishing it from traditional venture capital firms.
What is the geographic scope of Forepont's investments?
Forepont Capital Partners primarily invests in startups located in North America and Europe, focusing on regions with strong healthcare innovation ecosystems.
What is the typical check size for investments made by Forepont?
The firm typically invests between $1 million and $10 million in its portfolio companies, allowing for flexibility in supporting startups at various stages of development.
What kind of post-investment involvement does Forepont have with its portfolio companies?
Forepont provides extensive support to its portfolio companies, including scientific and technological guidance, operational expertise, and financial backing. The firm leverages its partnerships with researchers and industry stakeholders to enhance the growth and success of its investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.